Table 3.  

Number of primary and secondary events/total in included studies for the primary efficacy outcomes, and bleeding outcomes

Study, YearStroke and Systematic EmbolismRecurrent Thromboembolism or Thromboembolism-Related DeathCombined Bleeding EndpointMajor BleedingCRNB
DTI/FXaWarfarinDTI/FXaWarfarinDTI/FXaWarfarinDTI/FXaWarfarinDTI/FXaWarfarin
ARISTOTLE, 201254/149369/1512NANA123/1493211/151273/1493142/151250/149369/1512
EINSTEIN-DVT, 2010NANA4/1216/12913/12010/128NANANANA
EINSTEIN-PE, 2012NANA7/2115/19326/20934/192NANANANA
RECOVER, 2009NANA0/600/69NANA4/602/69NANA
REMEDY, 2013NANA1/591/49NANA2/593/49NANA
RE-LY, 200984/2379103/1092NANANANA244/2379116/1092NANA
ROCKET-AF, 201150/148160/1452NANA336/1498341/147299/1498100/1472261/1498259/1472
J-ROCKET, 20125/1416/143NANA42/14135/143NANANANA
  • DTI, direct thrombin inhibitor; FXa, factor Xa inhibitor; NA, not available.